Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GPC3 CAR-T cells for GPC3-positive advanced HCC
NCT03084380Phase 2
Key facts
- Status
- Unknown
- Start
- Jun 2017
- Primary completion
- May 2019
- Countries
- 1
- Sponsor
- Xinqiao Hospital
- Drugs
- BOXR1030
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of BOXR1030 in hepatocellular carcinoma (HCC), sponsored by Xinqiao Hospital. Primary endpoint: Safety at 4 weeks. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
anti-GPC3 CAR-T
TACE followed by lymphodepletion and anti-GPC3 CAR-T cell infusion.
03
Who it enrols
Patients with GPC3-positive advanced hepatocellular carcinoma who are unable to receive TACE combined with sorafenib; PS 0-2; life expectancy > 3 months; controlled HBV (DNA < 100/ml).
04
Endpoints
Primary
Safety
Secondary
Overall complete remission rate
Duration of CAR-positive T cells in circulation
Beyond the preview
Go deeper on NCT03084380.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084380.